Axogen Inc
$ 31.90
2.18%
26 Feb - close price
- Market Cap 1,566,283,000 USD
- Current Price $ 31.90
- High / Low $ 32.10 / 30.88
- Stock P/E N/A
- Book Value 2.73
- EPS -0.05
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.14 %
- 52 Week High 36.00
- 52 Week Low 9.22
About
AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.
Analyst Target Price
$39.20
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-08-05 | 2025-04-30 | 2025-02-25 | 2024-11-07 | 2024-08-08 | 2024-05-02 | 2024-03-05 | 2023-11-07 | 2023-08-07 | 2023-05-09 | 2023-03-14 |
| Reported EPS | 0.12 | 0.12 | -0.02 | 0.07 | 0.07 | 0.05 | -0.06 | -0.06 | 0.01 | -0.03 | -0.1 | -0.03 |
| Estimated EPS | 0.07 | 0.06 | 0.016 | 0.03 | 0.01 | -0.04 | -0.07 | -0.1 | -0.06 | -0.13 | -0.14 | -0.11 |
| Surprise | 0.05 | 0.06 | -0.036 | 0.04 | 0.06 | 0.09 | 0.01 | 0.04 | 0.07 | 0.1 | 0.04 | 0.08 |
| Surprise Percentage | 71.4286% | 100% | -225% | 133.3333% | 600% | 225% | 14.2857% | 40% | 116.6667% | 76.9231% | 28.5714% | 72.7273% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.0586 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | |
|---|---|---|
| Payment Date | None | None |
| Amount | $1.0 | $0.06 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AXGN
2026-02-25 16:52:30
AxoGen reported a strong fourth quarter and full-year 2025, with revenue up 21.3% and 20.2% respectively, driven by growth across multiple markets. Despite GAAP net losses, the company achieved an expanded full-year adjusted net income and EBITDA, and strengthened its balance sheet with a $133.3 million equity offering. Analysts have issued a Buy rating with a $42.00 price target, though TipRanks' AI Analyst, Spark, rates AXGN as Neutral due to financial quality and valuation concerns.
2026-02-25 11:52:30
HighMark Wealth Management LLC significantly increased its stake in Axogen (AXGN) by purchasing 158,855 shares, bringing its total holding to 343,940 shares valued at $11.2 million. This move makes Axogen one of HighMark's top five holdings, accounting for 4.6% of its reported assets under management, following a strong year for Axogen which included FDA approval for its Avance product and a 20% revenue surge. The investment firm's continued confidence in Axogen suggests a belief in its future growth potential and path to profitability.
2026-02-25 10:24:03
Axogen (AXGN) reported strong 21% revenue growth for Q4 2025, but missed EPS expectations, leading to an 8% share decline and highlighting margin pressures. The company is transitioning to a regulated biologics platform with Avance FDA approval, aiming for sustainable growth, 18%+ revenue guidance, and positive free cash flow in 2026. Despite a hold rating due to a stretched valuation, the company anticipates normalization of gross margin compression as biologics pricing and payer coverage expand.
2026-02-25 00:54:03
Axogen (AXGN) reported a Q4 2025 loss of US$13.2 million, despite revenue growth to US$59.9 million, bringing its trailing twelve-month net loss to US$15.7 million. This performance challenges the bullish narrative that spending on growth initiatives is a short-term hurdle, as losses widened from previous quarters. The company's premium P/S ratio of 7.2x, compared to an industry average of 3.0x, suggests little room for error as it remains unprofitable and relies on projected future growth and efficiency for a return to positive margins.
2026-02-24 13:54:03
HighMark Wealth Management LLC significantly increased its stake in Axogen (NASDAQ:AXGN) during the fourth quarter of 2025 by purchasing 158,855 shares, bringing its total holding to 343,940 shares valued at $11.2 million. This investment now represents 4.6% of HighMark's assets under management and follows a strong year for Axogen, which saw FDA approval for its Avance product and a 20% revenue surge. The firm's confidence in Axogen's future growth and path to profitability is highlighted.
2026-02-23 15:14:43
Axogen Inc. is scheduled to release its fourth-quarter earnings after a significant FDA approval for its Avance nerve graft product. Analysts predict earnings of 6 cents per share on $58.3 million in revenue, with strong optimism reflected in recent EPS estimate increases and an all-buy rating from covering analysts. The report will focus on commercial execution, margin improvements, and the company's competitive positioning in the peripheral nerve repair market.
